M
Marcel H. A. Muskiet
Researcher at VU University Medical Center
Publications - 44
Citations - 4875
Marcel H. A. Muskiet is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 19, co-authored 42 publications receiving 4058 citations. Previous affiliations of Marcel H. A. Muskiet include Vanderbilt University Medical Center.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
TL;DR: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure target of less than 120 mm Hg, as compared with less than 140 mm HG, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.
Journal ArticleDOI
Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
Lennart Tonneijck,Marcel H. A. Muskiet,Mark M. Smits,Erik J.M. van Bommel,Hiddo J.L. Heerspink,Daniël H. van Raalte,Jaap A. Joles +6 more
TL;DR: The revived interest in glomerular hyperfiltration as a prognostic and pathophysiologic factor in diabetes may lead to improved and timely detection of (progressive) kidney disease, and could provide new therapeutic opportunities in alleviating the renal burden in this population.
Journal ArticleDOI
GLP-1 and the kidney : from physiology to pharmacology and outcomes in diabetes
Marcel H. A. Muskiet,Lennart Tonneijck,Mark M. Smits,Michaël J.B. van Baar,Mark H. H. Kramer,Ewout J. Hoorn,Jaap A. Joles,Daniël H. van Raalte +7 more
TL;DR: The role of GLp-1 and the actions of associated therapies on glucose metabolism, the gut–renal axis, classical renal risk factors, and renal end points in randomized controlled trials of GLP-1 receptor agonists and DPP-4 inhibitors in patients with T2DM are reviewed.
Journal ArticleDOI
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Marcel H. A. Muskiet,Lennart Tonneijck,Yao Huang,Minzhi Liu,Aramesh Saremi,Hiddo J.L. Heerspink,Daniël H. van Raalte +6 more
TL;DR: An exploratory analysis of ELIXA investigated percentage change in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) according to prespecified albuminuria status at baseline and associated lixisenatide was associated with a reduced risk of new-onset macroalbuminuria.
Journal ArticleDOI
SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome
Erik J.M. van Bommel,Marcel H. A. Muskiet,Lennart Tonneijck,Mark H. H. Kramer,Max Nieuwdorp,Daniël H. van Raalte +5 more
TL;DR: Interestingly, in the recently reported first cardiovascular safety trial with a sodium-glucose cotransporter type 2 inhibitor, empagliflozin improved both renal and cardiovascular outcomes in patients with type 2 diabetes and established cardiovascular disease.